To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
Completion of capital increase in Initiator Pharma
Initiator Pharma A/S (“Initiator” or the “Company”) has today completed the capital increase directed at members of executive management and key management under the long term incentive program for 2023 (“LTI2023-program”), which was announced on 14 October 2024.
Slutförande av kapitalökning i Initiator Pharma
Initiator Pharma A/S (“Initiator” eller “Bolaget”) har idag slutfört den kapitalökning som riktats till ledande befattningshavare och nyckelpersoner i det långsiktiga incitamentsprogrammet för 2023 (“LTI2023-programmet”), som offentliggjordes den 14 oktober 2024.
Finalization of share buyback program in Initiator Pharma
Initiator Pharma A/S (“Initiator” or the “Company”) has today finalized the share buyback that was announced on 14 October 2024.
Slutförande av aktieåterköpsprogram i Initiator Pharma
Initiator Pharma A/S (“Initiativtagare” eller “Bolaget”) har idag slutfört det aktieåterköp som offentliggjordes den 14 oktober 2024
Beslut om nyemission och återköp av egna aktier samt försäljning av aktier i anslutning till det långsiktiga incitamentsprogrammet för 2023
Styrelsen för Initiator Pharma A/S, org.nr 37663808, (“Initiator” eller “Bolaget”) har idag beslutat att genomföra en kapitalökning riktad till ledande befattningshavare och nyckelpersoner inom ramen för det långsiktiga incitamentsprogrammet för 2023 (“LTI2023-programmet”) samt att genomföra ett återköp av egna aktier i marknaden i syfte att sälja aktier till styrelsen inom ramen för LTI2023-programmet.
Decision to issue new shares and conduct share buyback, as well as the sale of shares in connection with the long-term incentive program for 2023
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2023 (“LTI2023-program”) and to conduct a buyback of shares through the market in order to sell such treasury shares to the board of directors under the LTI2023-program.
Initiator Pharma A/S – Resolutions of the annual general meeting 2024
The annual general meeting of Initiator Pharma A/S (reg. no. 37663808 the “Company”) was held at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE on 24 May 2024 at 10.00 AM CEST.